{
  "study_id": "PFZ-738-D",
  "study_name": "PFZ-738-D",
  "sponsor": "PharmaFlex Industries",
  "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Long-term Efficacy and Safety of PFZ-738 in Patients with Early-Stage Parkinson's Disease",
  "phase": "3",
  "indication": "Parkinson's Disease",
  "therapeutic_area": "Neurology",
  "indication_level_quotes": "1687",
  "therapeutic_area_quotes": "12295",
  "population": {
    "age_range": "30 to 80 years",
    "condition": "Early-stage Parkinson's Disease",
    "inclusion_highlights": [
      "Clinical diagnosis of idiopathic Parkinson's disease",
      "Hoehn and Yahr stage 1-2.5",
      "Stable dopaminergic therapy for â‰¥ 4 weeks",
      "Motor fluctuations present"
    ]
  },
  "design": {
    "randomization": "Yes",
    "control": "Placebo-controlled",
    "blinding": "Double-blind",
    "arms": 2,
    "multicenter": true
  },
  "total_visits": 15,
  "visit_schedule_json": "pfz_738_d_visit_schedule.json"
} 